# Vaginal lIve Biotherapeutic RANdomized Trial

> **NCT06135974** · EARLY_PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 24 (actual)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** LC106
- **DRUG:** LC115
- **DRUG:** Placebo
- **DRUG:** Metronidazole Oral

## Key facts

- **NCT ID:** NCT06135974
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-01
- **Primary completion:** 2024-12-26
- **Final completion:** 2025-02-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135974, "Vaginal lIve Biotherapeutic RANdomized Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06135974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*